Đái tháo đường

Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping Thu5c &2
4
&#
#
&(8 /
:
"


"0
$" 
!! $$
%#$"$
&'#
"  )
($
$  >
4
8
$E
6"*
42D
15".
42m.(
42/.(
K*h5
)D"
$?$
15?
42B.)
$)58i.
)E"
Kd$
#*k4
,>
(*|
$)/
KOt.(
)58g4
q.
Kl.)
}
4)*g5
)w4
*.35,*.
4ON.(
Ko*
)/d$
458k4
Ko*
42/.(
K?*
4)?/
KOt.(
,>
$E
4)i
%`.
4s*
4B.)
42[.(
4I.(
KOt.(
)58g4
.()*A-
42m.(
h
,@5
%>*
#k.)
.)@.
+)F.(
KOv$
K*h5
42l
4o4
$?$
#*g.
$)y.(
42A.
6G.(
-[$
4)^.
+*.)
4)a.
6>
4*-
-[$)
3f
75]4
)*k.
J*h5
42l
#c.(
$?$
$)g
0)_-
*.35,*.
)/d$
$?$
4)5o$
K*h5
42l
K?*
4)?/
KOt.(
+)?$
\.(

3f
,>-
(*\-
4
,k
#*g.
$)y.(
6>
4{
6/.(
,*A.
15".
Kg.
K?*
4)?/
KOt.(
II B3NH %!
!
%'7 INSULIN Insulin aspart NOVOLOG Insulin detemir LEVEMIR Insulin glargine LANTUS Insulin glulisine APIDRA Insulin lispro HUMALOG NPH insulin suspension HUMULIN N, NOVOLIN N Regular insulin HUMULIN R, NOVOLIN R AMYLIN ANALOG Pramlintide SYMLIN ORAL AGENTS Acarbose PRECOSE Alogliptin NESINA Bromocriptine CYCLOSET Canagliflozin INVOKANA Colesevelam WELCHOL Dapagliflozin FARXIGA Glimepiride AMARYL Glipizide GLUCOTROL Glyburide DIAΒETA, GLYNASE PRESTAB Linagliptin TRADJENTA Metformin FORTAMET, GLUCOPHAGE Miglitol GLYSET Nateglinide STARLIX Pioglitazone ACTOS Repaglinide PRANDIN Rosiglitazone AVANDIA Saxagliptin ONGLYZA Sitagliptin JANUVIA Tolbutamide TOLBUTAMIDE 
,k
-b$
K?*
4)?/
KOt.(
K".(
(*"
4I.(
$)E.(
-d4
4[*
€
$M.(
.)O
42A.
4/>.
4)g
(*s*
(Ot*
4"
Os$
4C.)
$E

42*k5
(Ot*
€
6>

42*k5
(Ot*
42A.
4/>.
4)g
(*s*
K".(
0)\*
,>-
#[.
6s*
$I.
#k.)
>8
J?*
4)?/
KOt.(
+)F.(
0)\*
,>
-r4
#k.)
KN.
4)5^.
->
,>
-r4
.)E-
$?$
)r*
$)y.(
KOv$
Kd$
42O.(
$)5.(
#u*
4B.)
42[.(
4I.(
KOt.(
)58g4
%/
4)*g5
)w4
4ON.(
Ko*
)/d$
458k4
Ko*
*.35,*.
*k0
)r*
K?*
4)?/
KOt.(
€

0)@.
K?*
4)?/
KOt.(
JJ
4)>.)

.)E-
JJ
480&

JJ
480&

JJ
4)"*
+~
6>
$?$
4)i
Kd$
#*k4
(@8
2"
#u*
.(58A.
.)@.
+)?$
.)O
%*
4258h.
4)5o$
\.(

4E-
4b4
.)|.(
K*i-
Kd$
42O.(
$x"
K?*
4)?/
KOt.(
480&

6>
480&

J?*
4)?/
KOt.(
4)"*
+~
KOv$
Kl.)
()L"
,>
3}
2p*
,/[.
%5.(
.[0
(,5$/3&
+)u*
0)?4
)/d$
KOv$
$)_.
K/?.
,^.
K^5
42/.(
,H$
-".(
4)"*
J?*
4)?/
KOt.(
4)"*
+~
+)F.(
KOv$
+*i-
3/?4
4o4
$E
4)i
%`.
4s*
3*.)
$/.
4/
+)E
3*.)
$M.(
.)O
)[
KOt.(
)58g4
u
42e
KOv$
3*.)
2"
#u*
4)"*
0)w
-b$
#k.)
)g
Kr
I.
,>.)
-[.)
4a0
4)i
%w$
6>)/d$
3{
%w.(
*.35,*.
$E
)*k5
15\
4o4
$)/
.)|.(
#k.)
.)@.
INCRETIN MIMETIC K?*
4)?/
KOt.(
4)"*
+~
&4'/2-*.
6>
,8#52*%&
$E
4)i
3{
%w.(
4)"8
Exenatide BYETTA, BYDUREON Liraglutide VICTOZA 4)g
*.35,*.
42/.(
K*h5
42l
K?*
4)?/
KOt.(
4)"*
+~ A %#
#
&(8

 JJ
480&

4)Ot.(
(d0
u
42e
.)n
4)".)
4)*g5
.*A.
)/d$
.(Ot*
42e
45q*
u
-r4
3o
4)i
%*j.
4*g.
$)a-
#k.)
$E
4)i
75]4
)*k.
u
,y"
45q*
-5r.
)N.
JJ
480&

KOv$
Kd$
42O.(
#u*
3}
4)*g5
)w4
458k4
Ko*
*.35,*.
%/
4g
#>/
Q
#l
0)?
)x8
g
#>/
Q
#l
0)?
)x8
$E
4)i
,>
+g4
15\
$x"
15?
42B.)
4}
-*j.
KOv$
+)N*
->/
#u*
4?$
)@.
*253
)/d$
$?$
$)]4
Kr$
4z
-F*
42Ot.( 0002116803.INDD 335 B1ng 1 $;$
/
$%?
#A
@
$" 
3=%
$">
22 6/23/2014 8:28:59 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping       Type Type Tuổi khởi phát 5J
B!
5J
#%

$%I Thể trạng '
B!
0
!1 K
$"C

5J
$"C
$%I A' Tỷ suất mắc 5% - 10% 90% - 95% Liên quan di truyền M
!? @$
> Thiếu hụt, khiếm khuyết insulin D
-
6 G
!.
L'
@$
?
2
$D$
#% H
 >
$D$
 #%
.
#%
.
"H
 >
. g
%?0
T
.`5
,*_
/N/)
*0^5
Pr/)
569g/
5x9
,*I/)
P+h6
*G$
PSw&
PSt/)
*69g5
7?
%k/*
/*A/
O O
591(

&H
/*|/)
53+k6
&*z/)
P+i/
*E/*
&y$
5*+g6
*x5
+/46-+/
M/
/*+h6
6o/)
/*+h6
5+i6
/*+h6
)a9
/*+h6
k/*
/*A/
O O
591(

%d5
%6r&
1*_+
4{
'x/)
+/46-+/
Pi
53@/*
/*|/)
&R/
5N/)
PSt/)
*69g5
/)*+D.
53n/)
7?
/)69
*+i.
5F/*
.^/)
'0
/*+j.
50$/
&(50/( 
"
!
u
/)St+
%E/*
5*St/)
4$6
,*+
N/
1045$%40315+7(
5g
%?0
T
-6I/
5+g5
3$
.r5
-Sw/)
+/46-+/
*e/)
Pm/*
Pi
'69
53E
.z&
+/46-+/
/h/
O+h6
/?9
P_.
%_0
26@
53E/*
'm
*H$
-+1+'
1305+'
7?
)-9&0)(/
,*I/)
8_9
3$
$6
,*+
N/
,*0_/)

1*K5
5g
%?0
T
5+g5
3$
.r5
-Sw/)
+/46-+/
Pi
P@1
z/)
7s+
4}
5N/)
)-6&04(
7?
$&+'
$.+/
530/)
.@6
6@
53E/*
/?9
,C0
'?+
,*0_/)

1*K5
5+g1
4$6
PH
-?
26@
53E/*
5+g5
+/46-+/
4$6
N/
69
/*+D/
v
%k/*
/*A/
O O
591(

5g
%?0
T
%m
1*@
*y9
7?
,*I/)
5*i
P_.
%_0
Py
+/46-+/
/h/
&Q/)
/*S
-Sw/)
+/46-+/
&a/
Pi
P@1
z/)
7s+
5*$9
Pq+
/p/)
Pr
)-6&04(
530/)
.@6
_/)
 
#&
' Bk/*
/*A/
O O
591(

%6r&
1*_+
'J/)
+/46-+/
Pi
53@/*
5N/)
PSt/)
*69g5
/*+j.
50$/
&(50/(
7?
'69
53E
% 
v
.z&
&*`1
/*c/
PSw&
x&
5+D6
P+h6
53m
7s+
+/46-+/
-?
'69
53E
PSt/)
*69g5
)a/
z&

4+/*
-L
/*`5
&H
5*i
7?
53@/*
/*|/)
5*$9
Pq+
-s/
&y$
PSt/)
*69g5
*+
P+h6
53m
7s+
+/46-+/
5}
,+i.
53$
PSt/)
*69g5
5*St/)
869D/
%e/)
@9
P0
PSt/)
5^+
/*? Bng 
#.
33
$'!

&-
$'!
 
##

 O O
591(

&*+g.
Pg/
*R/
 
&@&
53St/)
*w1
O O
k/*
%m
_/*
*Sv/)
%v+
&@&
9g6
5o
/*S
'+
5369h/
56q+
%C0
1*E
,*@/)
+/46-+/
v
/)0^+
%+D/
*R/
-?
26@
53E/*
5}
.+j/
/*S
530/)
O O
591(

@&
3o+
-0^/
&*69i/
*H$
530/)
O O
591(

,*I/)
3a.
3r
/*S
530/)
O O
591(

!
%k/*
/*A/
O O
591(

5*St/)
,*I/)
%m
/*+j.
50$/
&(50/(
/*S/)
&@&
%+g/
&*z/)
.^/
5F/*
v

5*i
-?
5SR/)
5}
/*$6

 
µ µ Người khỏe mạnh 80 ĐTĐ type 40 ĐTĐ type 0 Phút 10 Truyền glucose TM  
 D$ #% K
5J
1
$5J
&-
F
/
33

$"%'E
% #
$4
> 0002116803.INDD 336  "
! O O
591(

Pf&
53S/)
%v+
5E/*
53^/)
,*@/)
+/46-+/

&R
26$/
PF&*
5*+g6
/*^9
&_.
7s+
+/46-+/
_/)

30/)
O O
591(

f&
'J
5g
%?0
T
7b/
&G/
,*_
/N/)
*0^5
Pr/)
/*S/)
-Sw/)
+/46-+/
5+g5
3$
,*I/)
Py
Pi
P+h6
*G$
PSt/)
*69g5
_/)

,*+
)f1
1*_+
5E/*
53$/)
,*@/)
+/46-+/
/)?9
&?/)
5N/)
v
/)0^+
%+D/
*o+
-Sw/)
5g
%?0
T
)+_.
'a/
5*(0
5*t+
)+$/
d&
%k/*
3@+
7s+
O O
591(

%k/*
/*A/
O O
591(

5*St/)
%C0
1*E
C0
1*E
-?
.r5
530/)
/*|/)
9g6
5o
)H1
1*a/
5^0
3$
5E/*
53^/)
,*@/)
+/46-+/

9g6
5o
PSw&
&0+
-?
/)69D/
/*A/
&*F/*
)A9
O O
591(
  #&
'
x&
5+D6
P+h6
53m
O O
591(

-?
'69
53E
PSt/)
*69g5
530/)
)+s+
*^/
%E/*
5*St/)
7?
/)N/
&*f/
53E
*0B/
5+g/
53+i/
&y$
&@&
%+g/
&*z/)
.^/
5F/*
+_.
&A/
5c1
5*i
'x&
P+h6
&*l/*
&*g
Pr
N/
-?.
)+_.
,*@/)
+/46-+/
7?
)+K1
.r5
4o
%k/*
/*A/
P^5
.z&
PSt/)
*69g5
x&
5+D6
569
/*+D/
*a6
*g5
&@&
%k/*
/*A/
Ph6
1*_+
4{
&@&
5*6o&
6o/)
P+h6
53m
O O
*(0
'+j/
5+g/
%k/*
5g
%?0
'a/
T
469
,+k5
,*+
PH
+/46-+/
5*St/)
PSw&
4{
'x/)
Pi
PS$
PSt/)
*69g5
7h
.z&
.x&
5+D6
_/)
 6/23/2014 8:29:00 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: 


  www.foxitsoftware.com/shopping III INSULIN VÀ INSULIN ANALOG +02)'+
);
&,/*,+#
!B
U+
!&V1
-#-1'"
!V2
1T,
1q
&'
!&2g'
-#-1'"
GKm!
+d'
3i'
+&2
[+%
*h1
!W2
+d'
"'02)$'"#
q
1'_+
!&V1
-/,'+02)'+
(&'
b
1&o5
-&=+
1T,
1&;+&
'+02)'+
3;
-#-1'"#
!U
&'
G_2
GKm!
1'^1
/
1q
125^+
1n5
K2
D
+02)'+
b
1&U'
1/q
.2
%+
3;
1&Y+
",
GB
+e+%
Gh
'+02)'+
1/,+%
*+
1n!
'+02)'+
"Ki'
"
!A+
%c'
);
J*
'+02)'+
&KJ+%
-&*
,T+
"Kl+%
*l
!B
1&`
GKm!
&T+
!&^
[+%
!*
a+&
+&=+
025
1&Y+
!B
1&`
!W+
%'U*
)'_2 0002116803.INDD 337 B"ng (8

6

 
7

0
& &


 # 9
'2
3

5

'/ 6/23/2014 8:29:02 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping namud.vn - Cng 


 
 Triệu chứng hạ đường huyết Đau đầu Hồi hộp IV CÁC CH


INSULIN TRONG  
 ! 168/-1
QUy(
(,-&
7,A1,
168/-1
1,&1,

&3-)
&(7-1+
168/-1
7,w-
+-&1
)8;
75G
7B(
)z1+
1+d1
 ,257
&(7-1+
7581+
'G1,
17*50*)-&7*
&(7-1+
9A
)A-
21+
&(7-1+
_1+

7J0
7d7
7,w-
+-&1
.,x-
3,B7
7B(
)z1+
Q^7
Qn1,
7521+
0B8
9A
)8;
75G
7B(
)z1+
({&
(B(
/2^-
-168/-1
Pr-
9v-
(B(
'B(
6R
,-
6~
)z1+
-168/-1
(a1
7,c1
75p1+
Qg(
'-m7
(,M
N
Qi1
/-j1
)L1+
9A
/2^-
-168/-1
QC;
/A
Q-j8
5`7
48&1
75p1+ A Insulin nhanh insulin th" Đánh trống ngực Lú lẫn Chóng mặt Toát mồ hôi Run Đói cồn cào Nhìn mờ A A A Mệt mỏi rã rời Loạn dưỡng mỡ Quá mẫn 
 ! . .
/

+ '-
-

#
+

,
#
%+
$
-
&
" 0002116803.INDD 338 J

(,i
3,b0
-168/-1
7,8u(
1,J0
1A;
 
'5

 

 
!%
 
 


 
%
2
 2
.
!%
 
&/
"
&3
'6
&4
1

0
-
168/-1
7,Uw1+
/A
/2^-
-168/-1
(J
7,w-
+-&1
)8;
75G
7B(
)z1+
1+d1
7&1
QUy(
(J
7,k
7^2
08r-
9v-
.h0
&
-168/-1
(I1
/^-
7,8u(
1,J0
 
 5&3-)
&(7-1+
+Uw-
7&
7,&;
Qs-
0u7
6r
&(-)
&0-1
7521+
-168/-1
7,Uw1+
Qk
7^2
5&
(B(
168/-1
&/&/2+

QJ
(,H1,
/A
(B(
 

#

 
.,B(
 
'5+
x
(,t
+r(
/;6-1*
9A
352/-1*
x
9o
75H

9A


(,8r-

,2B1
Qs-
9o
75H
(,2
1,&8

7,&;
Qs-
1A;
/A0
(,2
7,8r(
,`3
7,8
1,&1,
,T1
7B(
)z1+
:8`7
,-m1
1,&1,
,T1
9A
7,w-
+-&1
)8;
75G
7B(
)z1+
1+d1
,T1
6&8
.,-
7-F0
)Uv-
)&
!,w-
+-&1
Q^7
Qn1,
7521+
,8;i7
7UT1+
({&

 
.,2_1+

3,M7
62
9v-
 
3,M7
({&
 
'5

!%
 
 
(J
)Uy(
Qu1+
)Uy(
/(
7UT1+
7
1,U
-6352
-168/-1
,J0
-168/-1
1A;
QUy(
6~
)z1+
0K
3,q1+
-168/-1
+-_-
3,J1+
5&
7521+
.,-
O1
48&
QJ
.-k0
62B7
QUw1+
,8;i7
6&8
O1
1+2A-
5&
(S1+
QUy(
6~
)z1+
Qk
,^
QUw1+
,8;i7
1,&1,
.,-
(a1
,J0
1A;
7,Uw1+
QUy(
)L1+
3,r-
,y3
9v-
(B(
/2^-
-168/-1
1j1
7B(
)z1+
.E2
)A-

/2^-
1A;
)L1+
Qk
.-k0
62B7
QUw1+
,8;i7
QJ-
 
'5
3,_-
)L1+

3,M7
75Uv(
.,-
O1
7521+
.,-
 

(J
7,k
)L1+

3,M7
75Uv(
O1
,2g(
 
3,M7
6&8
.,-
'd7
Qa8
O1
168/-1
1,&1,
7,Uw1+
QUy(
6~
)z1+
1+2A-
'T0
-168/-1
5`7
7,H(,
,y3
7-F0
#
0g(
)L
-168/-1
7,Uw1+
QUy(
)L1+
'e1+
QUw1+
1A;
1,`7
.,-
(a1 B Insulin tác d#ng trung bình - NPH insulin 
 
/A
/2^-
(J
7,w-
+-&1
7B(
)z1+
7581+
'G1,
QUy(
7s1+
,y3
'e1+
(B(,
7,F0
h0
9A
3527&0-1*
9A2
-168/-1
7,Uw1+
2
i7
,y3
9v-
3527&0-1*
)Uv-
)^1+
3,|(
1F1
/2^-
-168/-1
1A;
H7
7&1
.i7
48_
/A
7,8r(
,`3
7,8
(,c0
7,w-
+-&1
)8;
75G
7B(
)z1+
)A-
,T1

-168/-1
QUy(
6~
)z1+
1,U
-168/-1
1j1
7521+
P!P
7;3*

9A

7,Uw1+
)L1+
D0
9v-
-168/-1
1,&1,
,2g(
-168/-1
7,Uw1+
Qk
.-k0
62B7
)Uw1+
,8;i7
6&8
O1

-168/-1
(,n
)L1+
7-F0
)Uv-
)&






(S1+

6~
)z1+
Qk
,^
QUw1+
,8;i7
7|(
7,G
1,U
7521+
1,-l0
72&1
(*721 C Insulin tác d#ng kéo dài P-k0
Qf1+
Q-m1
({&
s l
lare
7,`3
,T1
62
9v-
-168/-1
1+Uw-
(,2
1F1
,-
7-F0
6h
7^2
.i7
7{&
7^-
9o
75H
7-F0
6&8
QJ
7,8r(
QUy(
+-_-
3,J1+
7}
7}
!,w-
+-&1
:8`7
,-m1
7B(
)z1+
({&
1,J0
1A;
(,c0
,T1

"
.,B
'e1+
3,f1+
9A
.,K1+
(J
Qn1,
_1+
 6/23/2014 8:29:04 AM Edited with the trial version of Foxit Advanced PDF Editor  





 
  To remove this notice, visit: www.foxitsoftware.com/shopping Insulin aspart, insulin lispro, Insulin glulisine Regular insulin Nồng độ insulin huyết tương NPH insulin Insulin detemir Insulin glargine 12 Giờ 18 24 Bng %  # $     & '    %


"
 
   
  
:
!-["
"
7'
8&
K&!
"=(
,?&
B^&
$"8&
#S,
]"
$-%"&
,6
`&
#7'
5"
,BA&
,e
 
  
@0
$5
#S,
)-L
a
+e
"L"
(!:&
,c
,c
#!X"
(!b
!_(
]"
$-%"&
BA&
,e
"&+-$"&

.5
$* "&
 
  
@B_
+d
`&
$5%
"&+-$"&
&T&
6
$'K"
"&+-$"&
#!;&
:
,6
`&
#7'
5"
,!B^&
@B_
,*\&
.]"
6
$'K"
"&+-$"&
&50
,*'&

B^&
!-0S,
,*-&
&!
)
& B^"
&!
,!B^&
$5

%

!'Q
,!M(
!A&
b&
.]"

B]"
 
N&
+-M,
6
A&
!K
@B^&
!-0S,
!;&
%8
'
"%,
'
!K
@B^&
Q(
&!"T-
!A&
)
(!6
@(
@"T-
,*W
"&+-$"&
,9!
e
 L&

-0
&!"8&
U&!
&!&
+d
`&
(!6
@( @"T-
,*W
,9!
e
"L%
@6&
#'
6
"S&
!b&
%K!
%6-
&!X
&!B
"S&
!b&
.&
%K
,!%&
,!N&
#"&!
+'
.]"
(!6
@(
A
L&
 L&
 
!6
@(
@"T-
,*W
,9!
e
#!;&
#!-0S&
6'
!'
6
U&!
&!&
%&
U&!
$-
&?%
@ /-M,
!"U&
"S&
!b&
%K!
%6-
&!X
& B^"
'
,-Z"
.5
&!*&
& B^"
W
!K
@B^&
!-0S,
#!;&
*
& -08&
&!&
"T-
,*W
,9!
e
#!;&
$5%
"L%
"S&
!b&
%K!
%6-
$]&
)
U&!
&!&
@6"
,!6'
@B^&
0002116803.INDD 339 6/23/2014 8:29:05 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping Sáng Chiều Tối Insulin effect Thường Thường Thường B L S Morning Afternoon Đêm NPH Trước ngủ Evening Night Night S Insulin effect Morning Afternoon Lispro Lispro Night Glargine or detemir Insulin effect Lispro Evening B L S +6*(,
*)
3(>.
FHe-'
2!4

34b)
5=
3(e)
')!-
,W#
$Hd)

-D,
(U4
(Y3
FZ4
F>/
j-'
3`3
5d)
#>#
3(4`#
4`-'
E`)
5d)
"]-(
-(?-
+?4
-D,
#U-
/(`)
(g/
-()Z4
+.R)
3(4`#
4`-'
#B
3([
#B
(.X#
*(C-'
2l
$h-'
)-24+)-
F[
*)[,
2.>3
FHe-'
(47Y3
S-'


3(e)
')!-
3>#
$h-'
#i!
,c3
2`
3(4`#
4`-'
"=-'

,c3
2`
3>#
$h-'
/(h
3(He-'
'X/ A Nhóm sulfonylurea (B,
3(4`#
-=7
*A#(
3(A#(
3Y
"=.
I
3)Y3
)-24+)-
$.
FB
-B
FHg#
6Y/
5=.
-(B,
*A#(
3)Y3
)-24+)-
)]-
3R)
#>#
3(4`#
31.-'
-(B,
FHg#
2l
$h-'
-()Z4
+=
#>#
4+&.-7+41%!
3(Y
(]

"!.
'a,
 

+7 "%-#+!,)$%
  
 
5=
  Glyburide 18 h Glipizide 20 h Glimepiride 24 h Nateglinide h Repaglinide h Metformin 6h C
#

+ : G
#(Y
3>#
$h-'
#(A-(
#i!
3(4`#
+=


%

$
%
&
!
%

>#
4+&.-7+41%!
/(.-'
"Y
*@-(

/(h
3(4c#

'?7
*(l
#n#
,=-'
3Y
"=.
+=,
,f
*@-(
! 
+=,
3D-'
!  -c)
"=.
5=
')S)
/(B-'
-24+)-
3k
#>#
"_#
31.-'
-c)
"=.
(@,
5=.
FB
3(4`#
#B
3([
#B
3>#
$h-'
')S,
2S-
64T3
'+4#.2%
3R)
'!-
5=
3D-'
-(R7
#S,
)-24+)-
f
,C
-'.R)
")@- D*
(
& 

!4
*()
4`-'
3(4`#
+)@-
*Y3
5d)
/1.3%)-
(47Y3
3HG-'
(U4
(Y3
#>#
3(4`#
3(4c#
-(B,
-=7
+)@-
*Y3
1T3
,R-(
5d)
/1.3%3)-
(47Y3
3HG-'

$\
3HG-'
3>#

^#(
')S
3(4`#
FHg#
#(47[-
(B!
3R)
'!-
3(S)
31k
04!
-Hd#
3)[4
(.X#
/(?-
(e)
')!-
3>#
$h-'
#i!
#>#
2
3k


( 0002116803.INDD 341 Pioglitazone >24 h Acarbose 6h Miglitol 6h B"ng 10 (e)
')!-
3>#
$h-'
#i!
,c3
2`
3(4`#
4`-' 6/23/2014 8:29:08 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping Thu5c u5ng '3
4
'&
&
'(7 Glinide, Sulfonylureas Metformin, ức chế αGlucosidase Sulfonylurea, Glinides, TZD Metformin Ức chế DPP - GLUCOSE Hạ đường huyết Rối loạn tiêu hóa Tăng cân Buồn nôn Viêm tụy Bng 11 M6t s5
&
8
8
(7
0
9
&
5
'&
&
'(7 Tác dng ph
;
!m*$
*$+T&
D
%?*%
n
0%1d
+
$e)
0E*$
5087A5>;/+
(
2T
U
J-
=2>v-
€-
-2n
6/7
A=8-;86


72\
42J71
An=
-+
5373./
J-
=2>v-
28e=
2Q+
6/7
A=8-;86


72\
Barbiturate, Carbamazepine, Rifampin -Q
=2p
5I6
13f6
=J-
.~71
-+
=2>v-*
J-
=2>v-
2e
5393.
6J>
72\
/60,;3B35
€-
-2n
6/7
-2>Ap7
2Q+
=e3
1+7

-Q
=2p
5I6
=V71
71>A
-[
2e
X\{71
2>An=
-+
Glinide
.8
XQ
-2v71
-2s
Xt72
92v3
2}9

=2>v-
=;M7
2Q6
=2>v-
Glinide
-h7
v-
.>A
72g=
=;871
72Q6
-P7
X\}-

2I72
.8
71>A
-[
723q6
=8+7
5+-=3-
:>J
-+8
$>A
723M7
|
&3r=
+6
?i7
-Q
28e=
-2g=
7IA
=;M7
=2t
=;\{71
.\z3
.e71
…=2>v-
-l9†
@>g=
@€
$;>71
>v-

t-2
13f$2>v-
5I6
=V71
-8v-
42R71
1KA
=V71
=3n=
37537
:>J
6€-
?I
71>A
-[
2e
X\{71
2>An=
=2g9
2[7
#%
;g=
723o> [
-2n
=J-
.~71
-2O72
-+
Metformin
5I
13f6
g=
15>-8g=
15>-8J
6€-
=e3
1+7
5I
6y=
71>AM7
72K7
:>+7
=;u71
5I6
=V71
X\{71
2>An=
=;871
W$W
=A9/

f72
2\|71
-2
An>
5M7
X\{71
2>An=
XQ3*
Metformin
-Z71
5I6
-2j6
:>J
=;N72
2g9
=2>
X\{71
=e3
;>y=
5I6
=V71
,k=
13ƒ
?I
-8g=
23r7
?N
Metformin
5I6
6g=
-f6
13J-
7187
63r71

42>An7
-J8
Metformin
5I
-2s
Xt72
Xh>
=+A
=;871
X3o>
=;t
W$W
=A9/

Metformin
-Q
=2p
v-
>v71
42J-
e
X\{71
2>An=
-Q
=2p
@fA
;+
423
v-
4O-2
=3n=
7537
?N
?jA
-Q
=2p
92f3
-K7
72k-
X3o>
-2s72
53o> C
 

 : Metformin
2g9
=2>
=v=
:>+
X\{71
>v71
2h>
72\
42R71
53M7
4n=
?z3
9;8=/37
2>An=
=\[71
42R71
,t
-2>Ap7
2Q+
=2f3
=;•
|
.e71
71>AM7
?m7
:>+
7\z-
=3p> D

: +A
1V9
72g=
5I
;v3
58e7
=3M>
2Q+
/=08;637
-2v71
-2s
Xt72
-28
,r72
72K7
A
=2j7
/!
\z3

.8
5I6
=V71
71>A
-[
723q6
=8+7
5+-=3-
2f3
.•71
=2>v-
423
-Q
72w3
6J>
-[
=36
-g9
X}=
-g9
-+
A
=36
723q6
=;S71
2>An=
28l-
-J-
;v3
58e7
-Q
=2p
.i7
Xn7
A
=2j7
h7
x3
A
=36
7123r7
;\}>
h7
71•71
=2>v-
=;M7
-J-
,r72
72K7
92f3
v-
-f7
:>+71
X\{71
=Y72
6e-2
23q6
=8+7
5+-=3-
23n6
1l9
72\71
=„
5r
=‚
?871
;g=
-+8
S71
=2>v-
4L8
.I3
-Q
=2p
5I6
13f6
2g9
=2>
?3=+637
 Tác dng ph: 18I3
W$W
=A9/

Metformin
-P7
X\}-

=;t
2y3
-2€71
,>w71
=;€71
X+
7+71
Q
5I6
13f6
42J71
37537
=;871
2y3
-2€71
7IA
.i7
Xn7
;~71
=;€71
?I
,r72
72K7
-Q
=2p
=2~
=2+3 Ch

 : 0002116803.INDD 343 6/23/2014 8:29:10 AM Edited with the trial version of Foxit Advanced PDF Editor namud.vn - Cng 




 To remove this notice, visit: www.foxitsoftware.com/shopping D Nhóm thiazolidinedione (TZD) A%

%Q/)
-@.
5N/)
5F/*
/*^9
%_.
%y#
+/46-+/
#+
5*6o%
530/)
/*H.
$#0
)p
Pioglitazone 7@
Rosiglitazone.
d%
&K
+/46-+/
%a/
%*0
*0^5
Pr/)
%y#
5*6o%
/*S/)
/*H.
5*6o%
/@9
,*I/)
,F%*
5*F%*
5f
$@0
T
5+f5
+/46-+/
&0
PH
,*I/)
%H
/)69
%R
*^
PSt/)
*69f5
&0
5N/)
5+f5
26A
.z%
+/46-+/ A%

-@.
)+_.
,*A/)
+/46-+/
$c/)
%A%*
*0^5
Pr/)
/*S
.r5
%*`5
Pp/)
7b/
5*x
5*h
U
.r5
5*x
5*h
/c.
530/)
/*B/
5f
$@0
*x
5*h
U
PSw%
*0^5
*H#
4e
-@.
5*#9
Pq+
4#0
.C
%y#
.r5
4o
)'/'
269
Pl/*
*0^5
Pr/)
%y#
+/46-+/
*j
26_
-@
-@.
5N/)
Pr
/*^9
%_.
%y#
+/46-+/
7s+
%A%
.I
.v
)#/
%R
8SR/)
)St+
5#
%G/
26#/
5B.
Pf/
5A%
&x/)
%y#
5*6o%
-E/
/p/)
Pr
%*0-'45'30-
Rosigli-tazone
-@.
5N/)
53+)-9%'3+&'
530/)
,*+
Pioglitazone
-@.
)+_.
53+)-9%'3+&'
_
*#+
5*6o%
Pg6
-@.
5N/)


%*0-'45'30-

%H
5*h
&K/)
PR/
53l
-+j6
*0d%
1*o+
*w1
7s+
%A%
5*6o%
6o/)
,*A%
*0d%
+/46-+/
+g6
+/46-+/
%a/
)+_.
,*+
4|
&x/)
1*o+
*w1
7s+
/*H.
5*6o%
/@9

,*69f/
%A0
Pioglitazone
-@
-~#
%*m/
*@/)

*0d%

530/)
P+g6
53l
OO
591'

Rosiglitazone
F5
PSw%
4|
&x/)
&0
%A%
$+f/
%o
/d/)
53E/
5+.
.^%* C ch tác dng: Pioglitazone
7@
Rosiglitazone
Pg6
*`1
5*6
5o5
26#
PSt/)
6o/)
7@
-+E/
,f5
.^/*
7s+
#-$6.+/
*69f5
5SR/)
_
*#+
5*6o%
Pg6
%*69h/
*H#
.^/*
26#
%A%
+40:9.
 
,*A%
/*#6
r5
7@+
%*`5
%*69h/
*H#
%y#
Pioglitazone
%G/
*0^5
5F/*
Pioglitazone
F5
5*_+
53{
26#
5*b/
1*a/
-s/
5*6o%
7@
%A%
%*`5
%*69h/
*H#
PSw%
5*_+
53{
26#
&l%*
b5
530/)
1*B/
A%
%*`5
%*69h/
*H#
%y#
Rosiglitazone
PSw%
5*_+
53{
%*y
9f6
26#
/Ss%
5+h6
*I/)
%a/
%*k/*
-+g6
53E/
469
5*b/
569
/*+E/
53A/*
4|
&x/)
/*H.
5*6o%
/@9
%*0
1*x
/}
P#/)
%*0
%0/
$L D

: Tác dng ph:r5
7@+
53St/)
*w1
/*+i.
Pr%
)#/
PC
PSw%
$A0
%A0
,*+
&K/)
5*6o%
7@
5*'0
&J+
Pl/*
,
%*z%
/N/)
)#/
,*+
&K/)
5*6o%
PSw%
,*69f/
%A0
N/)
%B/
%H
5*h
86`5
*+j/
u
/*H.
/@9
&0
-@.
5N/)
.v
&Ss+
&#
7@
z
&l%*
*L
M
+}
/Ss%
%H
5*h
-@.
469
5+.
&+i/
5+f/
8`6
*R/
&0
PH
%a/
53A/*
4|
&x/)
/*H.
5*6o%
/@9
%*0
$j/*
/*B/
469
5+.
/d/)"

-+E/
26#/
Pf/
/)69
%R
.`5
8SR/)
7@
)C9
8SR/)
+0)-+5#:0/'
%H
5*h
-@.
5N/)
/)69
%R
6/)
5*S
$@/)
26#/)
r5
7@+
1*B/
5F%*
)r1
8A%
Pl/*
04+)-+5#:0/'
%H
5*h
-@.
5N/)
5€
-j
/*p+
.A6
%R
5+.
7@
5|
70/)
5+.
.^%*
f5
26_
-@
7+j%
4|
&x/)
04+)-+5#:0/'
%*k
A1
&x/)
%*0
%A%
Po+
5Sw/)
Pd%
$+j5
#6
,*+
8'.
8D5
5*E.
%A%
&}
-+j6
#/
50@/
7+j%
*^/
%*f
/@9
PC
PSw%
&v
$n SR/)
5~
/*S
'5(03.+/
-@.
)+_.
,*A/)
+/46-+/
%H
5*h
-@.
53z/)
3x/)
53u
-^+
u
%A%
1*x
/}
$l
*r+
53z/)
P#
/#/)
$6p/)
53z/)
530/)
5*t+
,
5+g/
.C/
,+/* Ch

: E Thuc 

α-glucosidase Acarbose  Miglitol
  *    ,
+
"(
)
! !

 0002116803.INDD 344 6/23/2014 8:29:10 AM Edited with the trial version of Foxit Advanced PDF Editor To remove this notice, visit: www.foxitsoftware.com/shopping /F4
)s
4/0m;
x
)w
)D4
*/a0
:854.
8;u:
W.2;*590+(9,
:/{>
6/F4
*(8)54/>+8(:,
:/D4/
2;*59,

+8(:,
+5
SM
2D3
.0a3
SVw4.
/;>l:
9(;
R4
5
1/N4.
1K*/
:0l:
049;204
/(>
2D3
:R4.
4/`>
*a3
049;204
4I4
4/M3
:/;s*
4D>
1/N4.
.F>
/`
SVw4.
/;>l:
1/0
9~
+z4.
SU4
:8q
20o;
;>
4/0I4
1/0
6/s0
/y6

*U
/`
SVw4.
/;>l:
*M
:/n
:R4.
2I4
%/P
Q
3u:
S0m;
7;(4
:8r4.
2D
1/0
)q
/`
SVw4.
/;>l:
*M
9~
+z4.
4/M3
:/;s*
4D>
4I4
S0m;
:8q
)h4.
.2;*59,
/U4
2D
+O4.
9(**(859,
SVw4.
;s4.
'!
+?
+7'!
-8
h'!
)"h
/7
!#8
-"7'"
':'
"#
-".a
-+:'
9.0% T ri ệu ng Đ ơn t rị liệ u * Ph ố i hợ p thuố c * Metformin GLP-1 RA SGLT-2i DPP-4i AGi TZD SU/GLN Không GLP-1 RA MET GLP-1 RA DPP-4i SGLT-2i Basal Insulin + Ph ố i h ợp t h uố c * SGLT-2i TZD thuốc hàng Colesevelam Bromocriptine QR AGi SU/GLN MET thuốc hàng + thuốc hàng + Nếu không đạt mục tiêu tháng chuyển sang phối hợp Nếu không đạt mục thuốc tiêu tháng chuyển qua phối hợp thuốc INSULIN Hoặc Thuốc khác ± Phối hợp thuốc Basal insulin DPP-4i Colesevelam Bromocriptine QR AGi Thêm insulin chuyển qua dùng Insulin SU/GLN Refer to Insulin Algorithm Nếu không đạt mục tiêu tháng LEGEND sulin phối hợp DIỄN Phối hợp thuốc TZD chuyển qua dùng In- * Thứ tự thuốc hàng xếp theo ưu tiên sử dụng Có Sử dụng thận trọng thêm Insulin TIẾN Ít tác dụng phụ, có thêm lợi ích BỆNH COPYRIGHT © 2015 AACE MAY NOT BE REPRODUCED IN ANY FORM WITHOUT EXPRESS WRITTEN PERMISSION FROM AACE Guideline hướng dẫn điều trị ĐTĐ type AACE 2015 e6 AACE/ACE Comprehensive Diabetes Management Algorithm, Endocr Pract 2015;21(No 4) To remove this notice, visit: www.foxitsoftware.com/shopping